Zacks Investment Research downgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to Sell in a report released today.
- Updated: September 20, 2016
Zacks Investment Research has downgraded Ironwood Pharmaceuticals, Inc.(NASDAQ:IRWD) to Sell in a statement released on 9/20/2016.
Previously on 7/15/2016, Mizuho Securities reported about Ironwood Pharmaceuticals, Inc.(NASDAQ:IRWD) bumped the target price from $16.00 to $24.00 that indicated a possible upside of 0.76%.
Yesterday Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded 1.68% higher at $15.01. Ironwood Pharmaceuticals, Inc.’s 50-day average is $13.75 and its 200-day moving average is $12.32. The last stock price close is up 22.91% from the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same time period. Trading volume was down over the average, with 1,032,951 shares of IRWD changing hands under the typical 1,148,230 shares..
See Chart Below:
Ironwood Pharmaceuticals, Inc. has a 52 week low of $7.35 and a one-year high of $15.33 and has a market cap of $0.0.
In addition to Zacks Investment Research reporting its target price, a total of 12 firms have issued a research note on the stock. The one year target stock price is $12.42 with two firms rating the stock a strong buy, three analysts rating the stock a buy, six analyts rating the stock a hold, one firm rating the stock to underperform, and finally 0 brokeragesrating the company as sell.
More About Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, and which include IW-1973 and IW-1701.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.